Active Not Recruiting PHASE1/PHASE2 INTERVENTIONAL 5-arm NCT02180711

Study of Acalabrutinib Alone or in Combination Therapy in Subjects With B-cell Non-Hodgkin Lymphoma

An Open-label, Phase 1b/2 Study of Acalabrutinib Alone or in Combination Therapy in Subjects With B-cell Non-Hodgkin Lymphoma

Sponsor: Acerta Pharma BV

Conditions Non Hodgkin Lymphoma

Interventions Lenalidomide acalabrutinib rituximab (IV)

Updated 21 times since 2017 Last updated: Sep 30, 2025 Started: Dec 29, 2014 Primary completion: Aug 25, 2023 Completion: Dec 29, 2028

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT02180711, this PHASE1/PHASE2 trial focuses on Non Hodgkin Lymphoma and remains ongoing. Sponsored by Acerta Pharma BV, it has been updated 21 times since 2014, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

21 versions recorded

Nov 2025 — Present [monthly]

Active Not Recruiting PHASE1/PHASE2
Sep 2025 — Nov 2025 [monthly]

Active Not Recruiting PHASE1/PHASE2
Sep 2024 — Sep 2025 [monthly]

Active Not Recruiting PHASE1/PHASE2
Aug 2024 — Sep 2024 [monthly]

Active Not Recruiting PHASE1/PHASE2
Jul 2024 — Aug 2024 [monthly]

Active Not Recruiting PHASE1/PHASE2

Phase: PHASE1_PHASE2 → PHASE1/PHASE2

▶ Show 16 earlier versions

May 2024 — Jul 2024 [monthly]

Active Not Recruiting PHASE1_PHASE2

Phase: PHASE1 → PHASE1_PHASE2
Mar 2024 — May 2024 [monthly]

Active Not Recruiting PHASE1
Dec 2023 — Mar 2024 [monthly]

Active Not Recruiting PHASE1
Jul 2023 — Dec 2023 [monthly]

Active Not Recruiting PHASE1
Apr 2023 — Jul 2023 [monthly]

Active Not Recruiting PHASE1
Sep 2022 — Apr 2023 [monthly]

Active Not Recruiting PHASE1
Jul 2022 — Sep 2022 [monthly]

Active Not Recruiting PHASE1
Apr 2022 — Jul 2022 [monthly]

Active Not Recruiting PHASE1

Status: Recruiting → Active Not Recruiting · Phase: PHASE1_PHASE2 → PHASE1
Jan 2021 — Apr 2022 [monthly]

Recruiting PHASE1_PHASE2
Jul 2019 — Jan 2021 [monthly]

Recruiting PHASE1_PHASE2
Mar 2019 — Jul 2019 [monthly]

Recruiting PHASE1_PHASE2
Jun 2018 — Mar 2019 [monthly]

Recruiting PHASE1_PHASE2
Mar 2018 — Jun 2018 [monthly]

Recruiting PHASE1_PHASE2

Status: Active Not Recruiting → Recruiting · Phase: PHASE1 → PHASE1_PHASE2
Dec 2017 — Mar 2018 [monthly]

Active Not Recruiting PHASE1
Feb 2017 — Dec 2017 [monthly]

Active Not Recruiting PHASE1
Jan 2017 — Feb 2017 [monthly]

Active Not Recruiting PHASE1

First recorded

Dec 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Acerta Pharma BV
AstraZeneca

Data source: Acerta Pharma BV

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Ann Arbor, United States , Bologna, Italy , Chicago, United States , Columbus, United States , Coral Gables FL, United States , Dallas, United States , Downey, United States , Duarte, United States , Edmonton, Canada , Fountain Valley, United States and 20 more locations